Resverlogix Corp. ("Resverlogix") (TSX:RVX), is pleased to announce today it will expand its research and development program for its lead technology NexVas™ into Stroke. The objective of this expansion is to address the crippling disease of Stroke and to fully develop the commercial opportunity for the company's current product pipeline in ApoA-1 enhancement therapies.
